Background: The objective of this study was to compare the rates of recurrence, additional treatment, patient satisfaction, and willingness to undergo Clostridium histolyticum (CCH) treatment again for Dupuytren disease in patients with and without skin tearing at minimum 5-year follow-up. Methods: We identified 199 digits in 142 patients who underwent CCH treatments for Dupuytren disease from April 2010 to December 2013 with minimum 5-year follow-up. Patients were contacted by telephone to collect our response variables: perceived recurrence of contracture, additional treatment, satisfaction, and willingness to undergo CCH treatment again. Medical records were reviewed for skin tearing at manipulation and patient-related and disease-specific variables. Results: At the time of manipulation, 16 out of 142 patients (11%) and 22 out of 199 digits (11%) had skin tearing. Older age was associated with skin tearing. At an average 7.2-year follow-up, the mean satisfaction was 7.1 ± 2.6 on a 1 to 10 Likert scale for patients with skin tearing and 6.5 ± 3.4 for patients without skin tearing. Eighty-one percent of patients with skin tearing expressed willingness to undergo CCH treatment again, compared with 68% of patients without skin tearing. Perceived recurrence of contracture occurred in 82% of digits with skin tearing and 80% of digits without skin tearing. Additional treatment was performed in 45% of digits with skin tearing and 54% of digits without skin tearing. No difference was statistically significant. Conclusions: Although skin tearing at CCH manipulation complicates the short-term course following CCH treatment, it does not affect long-term perceived contracture recurrence or patient satisfaction.
GilpinDColemanSHallS, et al. Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease. J Hand Surg Am. 2010;35(12):2027-2038.
2.
HurstLCBadalamenteMAHentzVR, et al. Injectable collagenase Clostridium histolyticum for Dupuytren’s contracture. N Engl J Med. 2009;361(10):968-979.
3.
PeimerCABlazarPColemanS, et al. Dupuytren contracture recurrence following treatment with collagenase Clostridium histolyticum (CORDLESS [collagenase option for reduction of dupuytren long-term evaluation of safety study]): 5-year data. J Hand Surg Am. 2015;40(8):1597-1605.
4.
LipmanMDCarstensenSEDealDN. Trends in the treatment of Dupuytren disease in the United States between 2007 and 2014. Hand. 2017;12(1):13-20.
5.
ZhaoJZHadleySFloydE, et al. The impact of collagenase Clostridium histolyticum introduction on Dupuytren treatment patterns in the United States. J Hand Surg Am. 2016;41(10):963-968.
6.
HweeYKParkDVinasM, et al. Outcome of Dupuytren contractures after collagenase Clostridium Histolyticum injection: a single-institution experience. Ann Plast Surg. 2017;79(2):145-148.
7.
WitthautJJonesGSkrepnikN, et al. Efficacy and safety of collagenase Clostridium histolyticum injection for Dupuytren contracture: short-term results from 2 open-label studies. J Hand Surg Am. 2013;38(1):2-11.
8.
ZhangDEarpBBlazarP. Risk factors for skin tearing in collagenase treatment of Dupuytren contractures. J Hand Surg Am. 2019;44(12):1021-1025.
9.
StrömbergJIbsen-SörensenAFridénJ. Comparison of treatment outcome after collagenase and needle fasciotomy for Dupuytren contracture: a randomized, single-blinded, clinical trial with a 1-year follow-up. J Hand Surg Am. 2016;41(9):873-880.
10.
StrömbergJIbsen SörensenAFridénJ. Percutaneous needle fasciotomy versus collagenase treatment for Dupuytren contracture: a randomized controlled trial with a two-year follow-up. J Bone Joint Surg Am. 2018;100(13):1079-1086.
11.
ZhouCHoviusSESlijperHP, et al. Collagenase Clostridium Histolyticum versus limited fasciectomy for Dupuytren’s contracture: outcomes from a multicenter propensity score matched study. Plast Reconstr Surg. 2015;136(1):87-97.
12.
ChenNCShauverMJChungKC. Cost-effectiveness of open partial fasciectomy, needle aponeurotomy, and collagenase injection for dupuytren contracture. J Hand Surg Am. 2011;36(11):1826-1834.
